Jun 22, 2024, 11:24
Neoadjuvant immunotherapy and SBRT in HCC
Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, shared a post on X:
“Neoadjuvant immunotherapy and SBRT in HCC – 3 x 8Gy on days 1, 3, 5 – 2 cycles of tislelizumab, every 21 days
- no delay of surgery, safe
- objective response rate (mRECIST) 63.2% (12/19), 3/19 CR
- pCR 2/19.“
Read further.
Source: Matthias Guckenberger/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 15:34
Nov 20, 2024, 15:23
Nov 20, 2024, 15:19
Nov 20, 2024, 14:56
Nov 20, 2024, 14:50
Nov 20, 2024, 14:44
Nov 20, 2024, 14:09
Nov 20, 2024, 13:52
Nov 20, 2024, 13:49